Compare American International Group Inc (AIG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs GeneDx Holdings Corp — how do they compare? American International Group Inc trades at $79.57 (market cap $42.98B), while GeneDx Holdings Corp trades at $65 (market cap $1.94B). The key difference: American International Group Inc is far larger — about 22.2× GeneDx Holdings Corp's market cap, and American International Group Inc pays a 2.47% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| AIG | WGS | |
|---|---|---|
Market Cap | $42.98B | $1.94B |
Sector | Financials | Technology |
52-Week High | $86.59 | $167.51 |
52-Week Low | $71.89 | $34.51 |
Enterprise Value | $50.68B | $1.94B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
GeneDx Holdings Corp. (WGS) trades at $68.89, up 2.04% today, with a bullish technical signal from moving averages and a consensus analyst price target of $75.40. Despite recent earnings beats in Q3 and Q4 2025, the company reported a net loss of -$21.02M in 2025, with profitability metrics like ROE at -30.42% reflecting operational challenges. The stock faces headwinds from a securities class action lawsuit alleging fraud, as noted in multiple legal alerts from July 2026.
The outlook is mixed: strong analyst buy ratings (90.91%) suggest upside potential, but negative margins and legal risks pose significant threats. Investors should weigh the high valuation multiples, such as EV/EBITDA of 161.17, against growth prospects in the genomics sector, with cash flow trends showing volatility into 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
